Phenoxymethylpenicillin (Penicillin V) - Bacterial infection
You are here : Home > Formulary Search > Phenoxymethylpenicillin (Penicillin V) - Bacterial infection
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Documentation
- No records returned.
PAD Profile
ChemicalSubstance :
Phenoxymethylpenicillin (Penicillin V)
Indication :
Bacterial infection
Group Name :
Keywords :
antibiotic, antibacterial, penicillin
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0
Other Indications
Below are listed other indications that Phenoxymethylpenicillin (Penicillin V) is used to treat.
- No records returned.
Other Drugs
Below are listed other drugs that are used to treat Bacterial infection.
- Amikacin
- Amoxicillin
- Azithromycin
- Aztreonam
- Benzylpenicillin sodium (Penicillin G)
- Cefaclor
- Cefalexin
- Cefepime
- Cefiderocol
- Cefixime
- Cefotaxime sodium
- Ceftazidime pentahydrate
- Ceftazidime with avibactam
- Ceftriaxone sodium
- Cefuroxime sodium
- Cetftolozone with tazobactam
- Chloramphenicol
- Ciprofloxacin
- Clarithromycin
- Clindamycin
- Co-amoxiclav
- Co-trimoxazole (Trimethoprim/sulfamethoxazole)
- Dalbavancin hydrochloride
- Dapsone
- Daptomycin
- Demeclocycline hydrochloride
- Doxycycline
- Ertapenem sodium
- Erythromycin
- Flucloxacillin sodium
- Fosfomycin
- Fusidic acid
- Gentamicin sulfate
- Imipenem with cilastatin
- Levofloxacin
- Meropenem
- Metronidazole
- Moxifloxacin
- Nitrofurantoin
- Norfloxacin
- Ofloxacin
- Piperacillin sodium/tazobactam sodium
- Rifabutin
- Sodium fusidate
- Streptomycin
- Sulfadiazine
- Teicoplanin
- Temocillin sodium
- Thalidomide
- Tigecycline
- Tinidazole
- Trimethoprim
- Vancomycin hydrochloride
Committee Recommendations (1)
The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.